Hot Flashes Treatment: Evidence-Based Options for Menopausal Women

Hot flashes treatment has changed significantly in the past three years, with the FDA approval of fezolinetant (Veozah) in 2023 marking the first major non-hormonal class of vasomotor symptom medication in over a decade. For the roughly 75% of women who experience hot flashes during the menopausal transition, options now span hormone therapy, neurokinin-3 receptor antagonists, SSRIs and SNRIs, gabapentinoids, cognitive behavioral therapy, and lifestyle modification. This guide synthesizes evidence from the 2022 NAMS Hormone Therapy Position Statement, the 2023 NAMS Nonhormone Therapy Position Statement, the ACOG 2023 Clinical Practice Guideline, and phase 3 trial data to summarize what works, what the trade-offs are, and what to discuss with a clinician.

Key facts at a glance

• Hormone therapy reduces moderate-to-severe hot flash frequency by approximately 75% versus 50% placebo response¹.
• Fezolinetant (Veozah) cut moderate-to-severe vasomotor symptoms by 55-65% in phase 3 SKYLIGHT trials³.
• Median duration of frequent vasomotor symptoms is 7.4 years per the SWAN cohort study⁴.
• Low-dose paroxetine 7.5mg is the only SSRI with specific FDA approval for vasomotor symptoms⁶.

What is the most effective hot flashes treatment?

The most effective hot flashes treatment for moderate-to-severe vasomotor symptoms is menopausal hormone therapy, according to the 2022 NAMS Hormone Therapy Position Statement¹. Across pooled randomized controlled trial data, systemic estrogen (with progestogen if a uterus is present) reduces the frequency of moderate-to-severe hot flashes by approximately 75%, compared with about a 50% reduction with placebo — a clinically meaningful net effect¹. The 2023 ACOG Clinical Practice Guideline reaffirms hormone therapy as first-line for healthy symptomatic women under 60 or within 10 years of menopause onset who have no contraindications⁷.

For women who cannot or prefer not to use hormone therapy, fezolinetant (Veozah) is now the most evidence-supported non-hormonal pharmacological option. In the SKYLIGHT 1 phase 3 trial, fezolinetant 45 mg daily reduced moderate-to-severe vasomotor symptom frequency by 55% at week 4 and 65% at week 12, versus 27% and 41% for placebo respectively³. The drug was approved by the FDA in May 2023 and works by blocking neurokinin-3 receptors on hypothalamic KNDy neurons that regulate thermoregulation⁵. Treatment selection ultimately depends on individual medical history, risk factors, symptom severity, and patient preference — a conversation to have with a clinician trained in menopause care.

How hot flashes treatment options compare

The 2023 NAMS Nonhormone Therapy Position Statement and the 2022 Hormone Therapy Position Statement together provide the most comprehensive evidence synthesis available, grading each intervention by strength of evidence¹². The following categories cover the bulk of clinically used options.

Hormone therapy

Systemic estradiol — oral (typically 0.5-1.0 mg daily), transdermal patch (0.025-0.1 mg/24h), gel, or spray — is the most effective intervention¹. Transdermal routes are often preferred when venous thromboembolism risk is a concern because they bypass first-pass hepatic metabolism and carry roughly half the VTE risk of oral formulations¹. Women with an intact uterus require a progestogen (micronized progesterone 100-200 mg, or a synthetic progestin) to prevent endometrial hyperplasia. The Women's Health Initiative long-term follow-up confirmed no increase in all-cause mortality among women initiating hormone therapy in the typical 50-59 age window⁸.

Fezolinetant (Veozah)

A neurokinin-3 receptor antagonist approved May 2023 at 45 mg once daily⁵. SKYLIGHT 1 demonstrated 55-65% reduction in moderate-to-severe vasomotor symptom frequency³. The FDA label includes a warning about hepatotoxicity, with required liver function monitoring at baseline, 3, 6, and 9 months⁵. Contraindicated in patients with cirrhosis or severe renal impairment.

SSRIs and SNRIs

Low-dose paroxetine 7.5 mg (Brisdelle) is the only non-hormonal medication FDA-approved specifically for vasomotor symptoms outside fezolinetant; pooled trials show approximately 30-40% reduction in hot flash frequency versus placebo⁶. Venlafaxine 75 mg, desvenlafaxine 100 mg, escitalopram 10-20 mg, and citalopram 10-20 mg are widely used off-label and supported by the 2023 NAMS non-hormone statement². Paroxetine and fluoxetine should be avoided in patients on tamoxifen due to CYP2D6 interaction².

Gabapentin and other agents

Gabapentin 900-2400 mg/day reduces vasomotor symptoms by approximately 45% and is particularly useful when night sweats dominate, given its sedating profile². Oxybutynin 2.5-5 mg twice daily and clonidine 0.1 mg/day have lower-tier evidence and notable side effect burdens².

Cognitive behavioral therapy

CBT specifically tailored for menopausal symptoms reduces symptom bother and frequency in randomized trials and is recommended by both NAMS and ACOG as a first-line non-pharmacological option². Clinical hypnosis has comparable evidence².

What does not have strong evidence

The 2023 NAMS Nonhormone Therapy Position Statement specifically does NOT recommend the following for vasomotor symptoms: paced respiration, supplements (black cohosh, dong quai, evening primrose oil, maca, omega-3s, pollen extract, vitamin E), cannabinoids, cooling techniques alone, exercise (helpful for health but not VSM frequency), mindfulness, weight loss as a standalone intervention, and yoga². These either failed to show benefit beyond placebo in well-conducted trials or had insufficient data to recommend². This does not mean they harm — only that they should not replace evidence-based options when symptoms are moderate-to-severe.

Telehealth provider options for hot flashes treatment

Several telehealth providers specialize in menopausal symptom management and can offer hot flashes treatment evaluation, prescribing, and ongoing care. Selection depends on insurance, treatment preference, and clinical complexity — discuss options with a primary care clinician or trusted source.

Midi Health accepts most commercial insurance plans and Medicare in many states, with NAMS-certified clinicians who manage hormone therapy, fezolinetant, SSRIs, and lifestyle interventions through video visits and asynchronous messaging.

Winona offers cash-pay async-first prescribing for HRT and non-hormonal options, with bioidentical formulations through partner compounding pharmacies and 24/7 messaging access to clinicians.

Alloy Women's Health provides cash-pay menopause care including HRT, the newer non-hormonal options, vaginal estrogen, and ongoing nurse support, with one-time onboarding and monthly subscription tiers.

Evernow is a cash-pay menopause-focused platform offering HRT, SSRIs, lifestyle coaching, and provider-led titration, with mobile-first symptom tracking.

Some brand mentions link to our editorial reviews. Coverage details, prescribing scope, and state availability vary — verify on each provider's site before enrollment.

Safety considerations and contraindications

Hormone therapy contraindications per the 2022 NAMS Position Statement include known or suspected estrogen-sensitive cancer, undiagnosed vaginal bleeding, active or recent venous thromboembolism, active liver disease, history of stroke or myocardial infarction, and pregnancy¹. Relative contraindications include uncontrolled hypertension, migraine with aura (consider transdermal route), gallbladder disease, and severe hypertriglyceridemia¹.

Fezolinetant carries a labeled hepatotoxicity warning; baseline liver function tests and follow-up at 3, 6, and 9 months are required, and use is contraindicated in cirrhosis⁵. SSRIs and SNRIs carry standard antidepressant warnings including suicidal ideation in younger adults, serotonin syndrome with combined serotonergic agents, and hyponatremia in older adults². Gabapentin can cause sedation, dizziness, and peripheral edema².

Urgent evaluation is warranted for hot flashes accompanied by unintended weight loss, fever, lymphadenopathy, or onset before age 40 — these may signal non-menopausal causes such as thyroid disease, carcinoid, lymphoma, or premature ovarian insufficiency, all of which require different workups¹⁷.

Cost and insurance considerations

Hot flashes treatment costs vary substantially by drug class, formulation, and insurance coverage. Generic oral estradiol commonly runs $10-30 per month at retail; transdermal estradiol patches range $30-100 monthly depending on brand and pharmacy¹. Micronized progesterone is generic and typically $20-50 monthly.

Fezolinetant retail price is approximately $550 per month before insurance, with manufacturer co-pay assistance programs that can reduce out-of-pocket cost to $30 for commercially insured patients⁵. Coverage by commercial insurers has expanded since 2024 but remains variable; prior authorization is common.

Low-dose paroxetine 7.5mg (Brisdelle, brand-only) runs $200-300 monthly; generic paroxetine 10-20 mg used off-label is typically under $20 monthly with insurance. Venlafaxine generic is similarly inexpensive. Gabapentin generic typically costs under $20 monthly.

Telehealth menopause consultations range from $100-400 for initial evaluation and $50-150 monthly for ongoing care, depending on whether visits are insurance-billed or cash-pay subscription models. Confirm in-network status and prior-authorization requirements with each provider before enrollment.

Frequently asked questions

What is the most effective hot flashes treatment?

Hormone therapy (estradiol with or without progestogen) remains the most effective hot flashes treatment, reducing moderate-to-severe vasomotor symptoms by approximately 75% versus 50% placebo response in NAMS-cited randomized trials. Treatment choice depends on individual risk factors and should be discussed with a clinician.

What is the best non-hormonal treatment for hot flashes?

Fezolinetant (Veozah), FDA-approved in May 2023, is the newest non-hormonal hot flashes treatment, cutting symptom frequency by 55-65% in phase 3 trials. Other evidence-supported options include low-dose paroxetine 7.5mg, venlafaxine 75mg, gabapentin, and CBT for menopausal symptoms.

How long do hot flashes last without treatment?

The Study of Women's Health Across the Nation (SWAN) found median total duration of frequent vasomotor symptoms was 7.4 years, with persistence after the final menstrual period averaging 4.5 years. Earlier-onset hot flashes (perimenopause) tend to last longer than late-onset symptoms.

Are natural remedies effective for hot flashes?

Evidence for botanical hot flashes treatment is mixed. Black cohosh, soy isoflavones, and red clover have shown small or inconsistent benefits in meta-analyses, often not significantly better than placebo. Cognitive behavioral therapy (CBT) and clinical hypnosis have stronger evidence for symptom bother reduction.

How much does hot flashes treatment cost?

Costs vary widely. Generic oral estradiol runs $10-30/month; transdermal patches $30-100/month with insurance. Fezolinetant retail price is approximately $550/month before insurance. Telehealth menopause consults range $100-400 for initial visit, $50-150/month for ongoing care.

When should I see a doctor about hot flashes?

Discuss hot flashes treatment with a clinician if vasomotor symptoms disrupt sleep, mood, or daily function, or if they begin before age 40 (possible premature menopause). Also seek evaluation for unusually severe night sweats with weight loss, fever, or other systemic symptoms that may indicate non-menopausal causes.

Sources

1. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
2. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. https://pubmed.ncbi.nlm.nih.gov/37252752/
3. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102. https://pubmed.ncbi.nlm.nih.gov/36924778/
4. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539. https://pubmed.ncbi.nlm.nih.gov/25686030/
5. US Food and Drug Administration. VEOZAH (fezolinetant) Prescribing Information. May 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216578s000lbl.pdf
6. Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013;20(10):1027-1035. https://pubmed.ncbi.nlm.nih.gov/24045679/
7. ACOG Clinical Practice Guideline No. 6: Management of Menopausal Symptoms. Obstet Gynecol. 2023;142(3):720-742. https://www.acog.org/clinical/clinical-guidance/clinical-practice-guideline/articles/2023/09/management-of-menopausal-symptoms
8. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938. https://pubmed.ncbi.nlm.nih.gov/28898378/

Related brands & guides

• Midi Health review — insurance-friendly menopause telehealth
• Winona review — cash-pay async HRT
• Alloy Women's Health review — subscription menopause care
• Evernow review — symptom-tracking menopause platform

Updated 2026-05-29. Reviewed by Dr. Maya Chen, MD, NAMS-CMP.